jim cramer eli lilly glp-1 on rising weight loss drugs and their market impact Wall Street is focused on
Description
The pressure is already visible
GLP-1 drug claims rose from 6.9% of employer plans in 2023 to 10.5% in 2025, according to Blue Cross Blue Shield data
The company is rolling out Boost Pre-meal, a liquid shot the Swiss giant said will "support people using GLP-1 receptor agonists or other weight-loss medications"
9,10 Upon glucose absorption in the small intestine, amylin is released from pancreatic -cells alongside insulin and exerts effects on both the peripheral and central nervous systems
Shan Y, Tan S, Lin Y, Liao S, Zhang B, Chen X, et al
